ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
1 hedge funds and large institutions have $9K invested in ELITE PHARMACEUTICAL in 2021 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
25% less capital invested
Capital invested by funds: $12K → $9K (-$3K)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IA
1
IFP Advisors
Tampa,
Florida
| $9K | – | – | – |
|
|
2
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$2K | -48,778 | Closed |
|
ELI Hedge Fund Activity: Q3 2021 in Review
1 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q3 2021, worth a combined $9K — down 25% from $12K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ELI and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was CAPTRUST Financial Advisors, exiting entirely with an estimated $2K sold.
- 1 institutional investor held ELITE PHARMACEUTICAL (ELI) as of Q3 2021, down from 2 in Q2 2021.
- Funds reported $9K of ELITE PHARMACEUTICAL stock for Q3 2021, down 25% quarter-over-quarter.
- 0 funds opened new ELITE PHARMACEUTICAL positions in Q3 2021 and 1 closed out, a net change of -1 holder.
- The largest ELITE PHARMACEUTICAL seller in Q3 2021 was CAPTRUST Financial Advisors, an estimated $2K sold.
Based on aggregated 13F filings for Q3 2021.